Paasa Logo
Novartis AG logo
NOVNSIXMarket closedOpens 9:00am CET

Novartis AG

CHF 121.40Last updated
+CHF 1.60 (1.34%)Past day
Timezone

Novartis AG (SIX: NOVN) is trading at CHF 121.40, about ₹14,048 at today's CHF/INR rate, as of 28 Sep 2026, 11:30 AM ET, up 1.34% today. Indian residents can buy Novartis from India on Paasa under the RBI's Liberalised Remittance Scheme.

Quote

Open:CHF 120.78
Previous close:CHF 119.80
Volume:3.00M

Today's low

CHF 120.50

Today's high

CHF 122.12

52 week low

CHF 97.05

52 week high

CHF 132.68

NOVN opened at CHF 120.78, closed previously at CHF 119.80, and has traded between CHF 97.05 and CHF 132.68 over the past 52 weeks.

About

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Country
CH
CEO
Vasant Narasimhan
Exchange listed on
SIX
Industry
Drug Manufacturers - General
Base currency
CHF
Full Time Employees
75,267
Sector
Healthcare
IPO date
08/03/1996

Key statistics

Avg. volume

2.85M

Market cap

CHF 230.75B

P/E Ratio

22.15

Price-to-sales ratio

5.06

Enterprise value

$318.91B

Free cash flow yield

5.76%

Debt-to-equity ratio

1.18

Return on equity

29.64%

ROIC

13.38%

Beta

0.49

Dividend yield

3.05%

Last dividend

CHF 3.70

Financial overview

Revenue

$57.13B

Earnings per share

$7.56

Free cash flow

$18.43B

Net profit margin

23.09%

Gross margin

74.29%

EBITDA

$23.96B

Revenue growth

10.45%

Similar securities

This is not an investment recommendation

How to buy Novartis from India

Indian residents can buy Novartis shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.

  1. Open a Paasa account

    Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.

  2. Add funds under LRS

    Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to CHF.

  3. Search for Novartis and place an order

    Find Novartis by name or by its ticker, NOVN, and choose an order type. Novartis trades 12:30 pm – 9:00 pm IST; orders can only execute during that window.

  4. Track holdings and download tax reports

    Follow your Novartis position in CHF and INR, and use Paasa's capital-gains and dividend statements when you file your Indian return.

Read the full guide: how to invest in Novartis from India

Trading and taxes when buying Novartis from India

Trading and limits

Trading hours
9:00 am – 5:30 pm CET
LRS limit
$250,000Per financial year, under the RBI's Liberalised Remittance Scheme.

Tax for Indian residents

TCS on remittance
20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
Capital gains in India
12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
Dividends
Slab rateDividends are taxed at your slab rate in India. Novartis’ current yield is 3.05%.Dividend tax explained

Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.

FAQs

Can Indian residents buy Novartis stock?

Yes. Novartis (NOVN) has been listed on the SIX Swiss Exchange since 1996, in the Drug Manufacturers - General industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to CHF. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.

How much does one Novartis share cost in rupees?

One Novartis share is CHF 121.40 — about ₹14,048 at a CHF/INR rate of 115.72 on 27 Sep 2026. Both the Novartis price and the rupee rate move during the day, so the rupee cost changes with them.

What are the LRS and TCS rules for buying Novartis from India?

Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.

How are gains on Novartis shares taxed in India?

Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the CHF/INR rate on the purchase and the sale date, so the rupee move counts alongside the Novartis price. Paasa issues a capital-gains statement for your return.

Does Novartis pay a dividend, and how is it taxed in India?

Yes. Novartis pays a dividend and the current yield is 3.05%; the last declared dividend was CHF 3.70 per share, about ₹428.16. Dividends are taxed at your slab rate in India. Paasa's dividend report lists the gross dividend and any tax withheld for each payment.

When can I trade Novartis from India?

The SIX Swiss Exchange trades 12:30 pm – 9:00 pm IST in Indian time. The window shifts to 1:30 pm – 10:00 pm IST when Switzerland is on standard time. Orders can only execute during that window.

Do I have to declare Novartis shares in my Indian tax return?

Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Novartis holding, its cost and its closing value.

How do I sell Novartis and bring the money back to India?

You sell during market hours (12:30 pm – 9:00 pm IST) and the proceeds settle in CHF in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.

Does the rupee rate affect what I make on Novartis?

Yes. Novartis is priced in CHF, so your rupee outcome combines the CHF move with the CHF/INR move between the day you remit and the day you convert back. Both directions are reflected in the capital-gains statement Paasa issues.